Education
About Us
Working with TipRanks
Follow Us
Altamira Therapeutics Ltd. (CYTOF)
:CYTOF
RESEARCH TOOLSreports
CYTOF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.05 - $1.53
Previous CloseN/A
Volume627.00
Average Volume (3M)8.83K
Market Cap
$354.36K
Enterprise ValueN/A
Total Cash (Recent Filing)$49.57K
Total Debt (Recent Filing)CHF3.47M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Sep 03, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding5,715,472
10 Day Avg. Volume3,529
30 Day Avg. Volume8,828
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Altamira Therapeutics News
PremiumCompany Announcements
Altamira Therapeutics Announces AGM Results and Board Elections
PremiumCompany Announcements
Altamira Therapeutics Announces June 2025 Annual General Meeting
PremiumCompany Announcements
Altamira Therapeutics Reports 2024 Financial Progress
PremiumCompany Announcements
Altamira Therapeutics Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Altamira Therapeutics Announces RNA Delivery Progress and Financial Results
PremiumCompany Announcements
Altamira Therapeutics Amends Revenue Sharing Agreement with Altamira MedicaOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.06% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
CYTOF FAQ
What was Altamira Therapeutics Ltd.’s price range in the past 12 months?
Altamira Therapeutics Ltd. lowest stock price was $0.05 and its highest was $1.53 in the past 12 months.
What is Altamira Therapeutics Ltd.’s market cap?
Altamira Therapeutics Ltd.’s market cap is $354.36K.
When is Altamira Therapeutics Ltd.’s upcoming earnings report date?
Altamira Therapeutics Ltd.’s upcoming earnings report date is Sep 03, 2025 which is in 54 days.
How were Altamira Therapeutics Ltd.’s earnings last quarter?
Altamira Therapeutics Ltd. released its earnings results on Apr 30, 2025. The company reported -$0.883 earnings per share for the quarter, missing the consensus estimate of -$0.61 by -$0.273.
Is Altamira Therapeutics Ltd. overvalued?
According to Wall Street analysts Altamira Therapeutics Ltd.’s price is currently Overvalued.
Does Altamira Therapeutics Ltd. pay dividends?
Altamira Therapeutics Ltd. does not currently pay dividends.
What is Altamira Therapeutics Ltd.’s EPS estimate?
Altamira Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Altamira Therapeutics Ltd. have?
Altamira Therapeutics Ltd. has 5,715,472 shares outstanding.
What happened to Altamira Therapeutics Ltd.’s price movement after its last earnings report?
Altamira Therapeutics Ltd. reported an EPS of -$0.883 in its last earnings report, missing expectations of -$0.61. Following the earnings report the stock price went up 12.5%.
Which hedge fund is a major shareholder of Altamira Therapeutics Ltd.?
Currently, no hedge funds are holding shares in CYTOF
Company Description
Altamira Therapeutics Ltd.
Altamira Therapeutics (CYTO) is a biopharmaceutical company focused on developing and commercializing RNA-based therapeutics. The company operates in the biotechnology sector, leveraging its proprietary technology platforms to create innovative treatments for various diseases, including inner ear disorders, nasal and allergy conditions, and other RNA-targeted therapies. Altamira aims to address unmet medical needs by advancing its pipeline of novel products through clinical development and regulatory approval.
CYTOF Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Altamira showed significant progress in its RNA delivery business with new partnerships and patent filings, while overcoming setbacks such as Nasdaq delisting and increased net loss. The strategy to involve private equity investors and spin-off RNA delivery activities indicates proactive steps for future growth.Read More>